clinical trial · NCT05521269
Dose Study of ANX1502 in Healthy Volunteers
HealthyANX1502Placebo
brief summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ANX1502 (prodrug) and ANX1439 (active drug) in healthy participants.
started
Jun 27, 2022
primary completion
Nov 19, 2024
completion
Nov 19, 2024
last updated
Dec 27, 2024
official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX1502 in Normal Healthy Volunteer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol